BofA Lowers PT on Danaher Corporation (DHR) to $220 From $230

Danaher Corporation (NYSE:DHR) is one of the best medical stocks to buy now. On September 22, BofA lowered the firm’s price target on Danaher Corporation (NYSE:DHR) to $220 from $230 while keeping a Buy rating on the shares.

The firm told investors that although some trends are showing stabilization and/or improvement in certain areas of Life Sciences and Diagnostic Tools, there exist several pockets of uncertainty and softness over the past year.

BofA expects these trends to persist for at least the next few quarters, which is why it is trimming forecasts for many core Tools companies and now expects a more gradual return to “normal.”

Danaher Corporation (NYSE:DHR) designs, manufactures, and markets professional, medical, industrial, and commercial products and services, making it a significant diagnostics stock. It operates through Diagnostics, Biotechnology, Life Sciences, and Environmental and Applied Solutions.

Its Biotechnology segment offers a range of equipment and consumables for biological medicines. In contrast, the Life Diagnostics segment offers clinical instruments, devices, consumables, and other services for diagnosing and treating diseases.

While we acknowledge the potential of DHR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.